Преимущества антагониста кальция – нифедипина ГИТС, при лечении артериальной гипертонии

В. Б. Мычка, Irina Evgen'evna Chazova · CARDIOVASCULAR THERAPY AND PREVENTION · 2008

Based on the results of international clinical trials, the clinical benefits of a dihydropyridine calcium antagonist, nifedipine GITS (slow-release gastrointestinal therapeutic-system) are discussed. Nifedipine GITS has been demonstrated to reduce cardiovascular morbidity and mortality effectively. The medication is safe and metabolically neutral even when administered as a long-term treatment.

Cited by 0 works.

Authors